Topical 5% tranexamic acid for the treatment of melasma in Asians: A double-blind randomized controlled clinical trial

Ayuthaya, Pinyapat Kanechorn Na; Niumphradit, Nucha; Manosroi, Aranya; Nakakes, Artit

doi:10.3109/14764172.2012.685478

Cited by 96 publications

(74 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8 Tranexamic acid is widely used as antifibrinolytic agent, it has recently been found to inhibit plasminogen-keratinocyte interaction which decreases tyrosinase activity leading to decrease melanin synthesis by melanocytes. 9,10 This is the first clinical study comparing single drug Tranexamic Acid in three different forms that is oral, soaks and cream in treatment of melasma. of oral tranexamic acid in treatment of melasma in Pakistani population : a pilot study conducted in 65 patients of melasma with oral tranexamic acid 250 mg twice a day for 6 months duration.…”

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy Profile of Oral Tranexamic Acid v/s Tranexamic Acid Soaks v/s Tranexamic Acid Cream in Treatment of Melasma – A Hospital Based Prospective Randomised Controlled Comparative Study

Patil¹

2018

jmscr

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy Profile of Oral Tranexamic Acid v/s Tranexamic Acid Soaks v/s Tranexamic Acid Cream in Treatment of Melasma – A Hospital Based Prospective Randomised Controlled Comparative Study

Patil¹

2018

jmscr

View full text Add to dashboard Cite

“…oral, topical and localized microinjections) have shown promising results (7,(9)(10)(11), there is a lack of support for its efficacy and safety in melasma due to the absence of sufficiently powered randomized controlled trials (RCTs). Through a systematic review of the literature, we aimed to investigate the effectiveness and safety of TA, alone, or as an adjuvant, in patients with melasma.…”

mentioning

confidence: 99%

Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review

Kim¹,

Moon²,

Cho³

et al. 2017

Acta Derm Venerol

View full text Add to dashboard Cite

“…Four clinically heterogeneous trials were identified in the area of aesthetic surgery, involving 365 patients [39][40][41][42] but all 4 assessed the use of TXA as a lightening agent for melasma in oriental and/or Asian skin, including 2 studies investigating the use of oral TXA in conjunction with laser depigmentation. Tranexamic acid has also been reported as a constituent of tumescent solution in hair transplant surgery 43 and liposuction.…”

Section: Aestheticmentioning

confidence: 99%

The Efficacy and Safety of Tranexamic Acid in Cranio-Maxillofacial and Plastic Surgery

Murphy

Glass

Jain

2016

Journal of Craniofacial Surgery

View full text Add to dashboard Cite

The antifibrinolytic drug tranexamic acid (TXA) is effective in reducing blood loss and transfusion requirements in other fields of elective surgery and its use is emerging in a number of plastic surgical subspecialties. This systematic review and meta-analysis evaluates the current evidence for the efficacy and safety of TXA in craniomaxillofacial, head and neck, breast, aesthetic, burns, and reconstructive microsurgery. We searched PubMed, EMBASE, Medline, The Cochrane Database of Systematic Reviews and the Cochrane Central Register of Controlled Trials for randomized controlled trials of TXA in plastic surgery. Studies were analyzed using standard methodology. A total of 7965 records were screened, of which 14 met the inclusion criteria. Seven were suitable for meta-analysis. In craniofacial surgery, TXA was associated with a mean reduction in blood loss of 18.2 mL/kg (P = 0.00001) and a mean reduction in blood transfusion of 8.7 mL/kg (P = 0.0001). In orthognathic surgery, TXA was associated with a mean reduction in blood loss of 156 mL (P = 0.001). Tranexamic acid may also have a role in reducing drainage output volumes in oncological breast excision and lymph node dissection of the neck. Level-1 evidence for efficacy in aesthetic surgery, burns, and reconstructive microsurgery is lacking. Although no reported complications were attributable to TXA, there remain no phase IV trials published. Level-1 evidence supports the use of TXA in craniofacial and orthognathic surgery. There exists an unmet need for studies in areas, including burns, aesthetic surgery, and reconstructive microsurgery. Phase IV trials in areas of proven efficacy are also required.

show abstract

Topical 5% tranexamic acid for the treatment of melasma in Asians: A double-blind randomized controlled clinical trial

Abstract: Although lightening of pigmentation was obtained, the results were not significant between the two regimens. However, topical TA produced erythema.

Cited by 96 publications

References 17 publications

Safety and Efficacy Profile of Oral Tranexamic Acid v/s Tranexamic Acid Soaks v/s Tranexamic Acid Cream in Treatment of Melasma – A Hospital Based Prospective Randomised Controlled Comparative Study

Safety and Efficacy Profile of Oral Tranexamic Acid v/s Tranexamic Acid Soaks v/s Tranexamic Acid Cream in Treatment of Melasma – A Hospital Based Prospective Randomised Controlled Comparative Study

Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review

The Efficacy and Safety of Tranexamic Acid in Cranio-Maxillofacial and Plastic Surgery

Contact Info

Product

Resources

About